biologics Archives - Drugs in Context

Considerations for the US health-system pharmacist in a world of biosimilars

Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

Article Type

Editorial

Published

25 Feb 2020

This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

Novel therapeutic targets for allergic airway disease in children

Alessandro Giallongo MD, Giuseppe Fabio Parisi MD, Amelia Licari MD, Giulio Pulvirenti MD, Caterina Cuppari MD, Carmelo Salpietro MD, Gian Luigi Marseglia MD, Salvatore Leonardi MD

Article Type

Review

Published

09 Jul 2019

The biosimilars journey: current status and ongoing challenges

Igor Age Kos MD, Valderílio Feijó Azevedo MD, PhD, Daniel Egg Neto, Sérgio Cândido Kowalski MD, PhD

Article Type

Review

Published

01 Oct 2018

Biosimilar products are already approved and marketed in several countries. This review focuses on remaining challenges regarding biosimilars, such as the lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases.